Skip to main content
SpringerLink
Log in
Book cover

Advances in Cancer Biomarkers pp 9–26Cite as

Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 867))

Abstract

Cancer is one of the major public health problems worldwide representing the leading cause of morbidity and mortality in industrialized countries. To reduce cancer morbidity and mortality as well as to facilitate the evolution from the traditional “one size fits all” strategy to a new “personalized” cancer therapy (i.e., the right drug to the right patient at the right time, using the right dose and schedule), there is an urgent need of reliable, robust, accurate and validated cancer biomarker tests.

Unfortunately, despite the impressive advances in tumor biology research as well as in high-powerful “omics” technologies, the translation of candidate cancer biomarkers from bench to bedside is lengthy and challenging and only a few tumor marker tests have been adopted successfully into routine clinical care of oncologic patients.

This chapter provides an updated background on biomarkers research in oncology, including biomarkers clinical uses, and discusses the problems of discovery pipeline, biomarkers failures and future perspectives.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. La Thangue NB, Kerr DJ (2011) Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 8(10):587–596. doi:10.1038/nrclinonc.2011.121

    Article  PubMed  CAS  Google Scholar 

  2. National Cancer Institute (2014) Lifetime risk tables. Available on line: http://seer.cancer.gov/csr/1975_2011/results_merged/topic_lifetime_risk.pdf. Accessed 31 Dec 2014

  3. GLOBOCAN (2012) Available online: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 31 Dec 2014

  4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.1002/ijc.29210

    Article  CAS  PubMed  Google Scholar 

  5. Makawita S, Diamandis EP (2010) The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem 56(2):212–222. doi:10.1373/clinchem.2009.127019

    Article  CAS  PubMed  Google Scholar 

  6. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95. doi:10.1067/mcp.2001.113989

    Article  Google Scholar 

  7. Fuzery AK, Levin J, Chan MM, Chan DW (2013) Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 10(1):13. doi:10.1186/1559-0275-10-13

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  8. Duffy MJ (2013) Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract 22(1):4–11. doi:10.1159/000338393

    Article  PubMed  Google Scholar 

  9. Kulasingam V, Diamandis EP (2008) Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 5(10):588–599. doi:10.1038/ncponc1187

    Article  CAS  PubMed  Google Scholar 

  10. Henry NL, Hayes DF (2012) Cancer biomarkers. Mol Oncol 6(2):140–146. doi:10.1016/j.molonc.2012.01.010

    Article  CAS  PubMed  Google Scholar 

  11. Paoletti C, Hayes DF (2014) Molecular testing in breast cancer. Annu Rev Med 65:95–110. doi:10.1146/annurev-med-070912-143853

    Article  CAS  PubMed  Google Scholar 

  12. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A (2011) Integrating biomarkers in clinical trials. Expert Rev Mol Diagn 11(2):171–182. doi:10.1586/erm.10.120

    Article  PubMed  Google Scholar 

  13. Duffy MJ, Crown J (2008) A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 54(11):1770–1779. doi:10.1373/clinchem.2008.110056

    Article  CAS  PubMed  Google Scholar 

  14. Sawyers CL (2008) The cancer biomarker problem. Nature 452(7187):548–552. doi:10.1038/nature06913

    Article  CAS  PubMed  Google Scholar 

  15. Simon R, Roychowdhury S (2013) Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 12(5):358–369. doi:10.1038/nrd3979

    Article  CAS  PubMed  Google Scholar 

  16. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML (2011) NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 9(Suppl 5):S1–32, quiz S33

    CAS  Google Scholar 

  17. Sargent DJ, Conley BA, Allegra C, Collette L (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23(9):2020–2027. doi:10.1200/JCO.2005.01.112

    Article  PubMed  Google Scholar 

  18. Duffy MJ, Crown J (2014) Precision treatment for cancer: role of prognostic and predictive markers. Crit Rev Clin Lab Sci 51(1):30–45. doi:10.3109/10408363.2013.865700

    Article  CAS  PubMed  Google Scholar 

  19. Duffy MJ, O’Donovan N, Crown J (2011) Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 37(2):151–159. doi:10.1016/j.ctrv.2010.07.004

    Article  CAS  PubMed  Google Scholar 

  20. August J (2010) Market watch: emerging companion diagnostics for cancer drugs. Nat Rev Drug Discov 9(5):351. doi:10.1038/nrd3173

    Article  CAS  PubMed  Google Scholar 

  21. Gainor JF, Longo DL, Chabner BA (2014) Pharmacodynamic biomarkers: falling short of the mark? Clin Cancer Res 20(10):2587–2594. doi:10.1158/1078-0432.CCR-13-3132

    Article  CAS  PubMed  Google Scholar 

  22. Guchelaar HJ, Gelderblom H, van der Straaten T, Schellens JH, Swen JJ (2014) Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing. Clin Pharmacol Ther 95(4):383–385. doi:10.1038/clpt.2014.13

    Article  CAS  PubMed  Google Scholar 

  23. Sarker D, Workman P (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 96:213–268. doi:10.1016/S0065-230X(06)96008-4

    Article  CAS  PubMed  Google Scholar 

  24. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Brana I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G (2014) Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 20(1):233–245. doi:10.1158/1078-0432.CCR-13-1777

    Article  CAS  PubMed  Google Scholar 

  25. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM (2012) Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 4(127):127rv123. doi:10.1126/scitranslmed.3003180

    Article  CAS  Google Scholar 

  26. Negm RS, Verma M, Srivastava S (2002) The promise of biomarkers in cancer screening and detection. Trends Mol Med 8(6):288–293

    Article  CAS  PubMed  Google Scholar 

  27. Kanwal R, Gupta S (2012) Epigenetic modifications in cancer. Clin Genet 81(4):303–311. doi:10.1111/j.1399-0004.2011.01809.x

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. You JS, Jones PA (2012) Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22(1):9–20. doi:10.1016/j.ccr.2012.06.008

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Nogueira da Costa A, Herceg Z (2012) Detection of cancer-specific epigenomic changes in biofluids: powerful tools in biomarker discovery and application. Mol Oncol 6(6):704–715. doi:10.1016/j.molonc.2012.07.005

    Article  CAS  PubMed  Google Scholar 

  30. Barrow TM, Michels KB (2014) Epigenetic epidemiology of cancer. Biochem Biophys Res Commun 455(1–2):70–83. doi:10.1016/j.bbrc.2014.08.002

    Article  CAS  PubMed  Google Scholar 

  31. Coppede F, Lopomo A, Spisni R, Migliore L (2014) Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol 20(4):943–956. doi:10.3748/wjg.v20.i4.943

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  32. Sandoval J, Peiro-Chova L, Pallardo FV, Garcia-Gimenez JL (2013) Epigenetic biomarkers in laboratory diagnostics: emerging approaches and opportunities. Expert Rev Mol Diagn 13(5):457–471. doi:10.1586/erm.13.37

    Article  CAS  PubMed  Google Scholar 

  33. Toiyama Y, Okugawa Y, Goel A (2014) DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun. doi:10.1016/j.bbrc.2014.08.001

    PubMed  PubMed Central  Google Scholar 

  34. Konforte D, Diamandis EP (2013) Is early detection of cancer with circulating biomarkers feasible? Clin Chem 59(1):35–37. doi:10.1373/clinchem.2012.184903

    Article  CAS  PubMed  Google Scholar 

  35. Pavlou MP, Diamandis EP, Blasutig IM (2013) The long journey of cancer biomarkers from the bench to the clinic. Clin Chem 59(1):147–157. doi:10.1373/clinchem.2012.184614

    Article  CAS  PubMed  Google Scholar 

  36. Buchen L (2011) Cancer: missing the mark. Nature 471(7339):428–432. doi:10.1038/471428a

    Article  CAS  PubMed  Google Scholar 

  37. Diamandis EP (2010) Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 102(19):1462–1467. doi:10.1093/jnci/djq306

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Dunn BK, Wagner PD, Anderson D, Greenwald P (2010) Molecular markers for early detection. Semin Oncol 37(3):224–242. doi:10.1053/j.seminoncol.2010.05.007

    Article  CAS  PubMed  Google Scholar 

  39. Ransohoff DF (2008) The process to discover and develop biomarkers for cancer: a work in progress. J Natl Cancer Inst 100(20):1419–1420. doi:10.1093/jnci/djn339

    Article  CAS  PubMed  Google Scholar 

  40. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93(14):1054–1061

    Article  CAS  PubMed  Google Scholar 

  41. Ransohoff DF (2007) How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 60(12):1205–1219. doi:10.1016/j.jclinepi.2007.04.020

    Article  PubMed  Google Scholar 

  42. Witkowska HE, Hall SC, Fisher SJ (2012) Breaking the bottleneck in the protein biomarker pipeline. Clin Chem 58(2):321–323. doi:10.1373/clinchem.2011.175034

    Article  CAS  PubMed  Google Scholar 

  43. Heckman-Stoddard BM (2012) Oncology biomarkers: discovery, validation, and clinical use. Semin Oncol Nurs 28(2):93–98. doi:10.1016/j.soncn.2012.03.003

    Article  PubMed  Google Scholar 

  44. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24(8):971–983. doi:10.1038/nbt1235

    Article  CAS  PubMed  Google Scholar 

  45. Frangogiannis NG (2012) Biomarkers: hopes and challenges in the path from discovery to clinical practice. Transl Res 159(4):197–204. doi:10.1016/j.trsl.2012.01.023

    Article  PubMed Central  PubMed  Google Scholar 

  46. Schwamborn K (2012) Imaging mass spectrometry in biomarker discovery and validation. J Proteomics 75(16):4990–4998. doi:10.1016/j.jprot.2012.06.015

    Article  CAS  PubMed  Google Scholar 

  47. Schiess R, Wollscheid B, Aebersold R (2009) Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 3(1):33–44. doi:10.1016/j.molonc.2008.12.001

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Zhang Z, Chan DW (2010) The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 19(12):2995–2999. doi:10.1158/1055-9965.EPI-10-0580

    Article  CAS  PubMed  Google Scholar 

  49. McShane LM, Hayes DF (2012) Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol 30(34):4223–4232. doi:10.1200/JCO.2012.42.6858

    Article  PubMed Central  PubMed  Google Scholar 

  50. Wagner PD, Srivastava S (2012) New paradigms in translational science research in cancer biomarkers. Transl Res 159(4):343–353. doi:10.1016/j.trsl.2012.01.015

    Article  PubMed Central  PubMed  Google Scholar 

  51. Hayes DF (2013) OMICS-based personalized oncology: if it is worth doing, it is worth doing well! BMC Med 11:221. doi:10.1186/1741-7015-11-221

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  52. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO (2009) The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med 11(1):3–14. doi:10.1097/GIM.0b013e318184137c

    Article  PubMed Central  PubMed  Google Scholar 

  53. Hayes DF (2013) From genome to bedside: are we lost in translation? Breast 22(Suppl 2):S22–S26. doi:10.1016/j.breast.2013.07.004

    Article  PubMed  Google Scholar 

  54. Linnet K, Bossuyt PM, Moons KG, Reitsma JB (2012) Quantifying the accuracy of a diagnostic test or marker. Clin Chem 58(9):1292–1301. doi:10.1373/clinchem.2012.182543

    Article  CAS  PubMed  Google Scholar 

  55. de Gramont A, Watson S, Ellis LM, Rodon J, Tabernero J, Hamilton SR (2014) Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol. doi:10.1038/nrclinonc.2014.202

    PubMed  Google Scholar 

  56. Behrens T, Bonberg N, Casjens S, Pesch B, Bruning T (2014) A practical guide to epidemiological practice and standards in the identification and validation of diagnostic markers using a bladder cancer example. Biochim Biophys Acta 1844(1 Pt A):145–155. doi:10.1016/j.bbapap.2013.07.018

    Article  CAS  PubMed  Google Scholar 

  57. Jennings L, Van Deerlin VM, Gulley ML (2009) Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med 133(5):743–755. doi:10.1043/1543-2165-133.5.743

    PubMed  Google Scholar 

  58. Diamandis EP (2014) Present and future of cancer biomarkers. Clin Chem Lab Med 52(6):791–794. doi:10.1515/cclm-2014-0317

    CAS  PubMed  Google Scholar 

  59. Drabovich AP, Martinez-Morillo E, Diamandis EP (2014) Toward an integrated pipeline for protein biomarker development. Biochim Biophys Acta. doi:10.1016/j.bbapap.2014.09.006

    PubMed  Google Scholar 

  60. Sahab ZJ, Semaan SM, Sang QX (2007) Methodology and applications of disease biomarker identification in human serum. Biomark Insights 2:21–43

    PubMed Central  PubMed  Google Scholar 

  61. Li J, Kelm KB, Tezak Z (2011) Regulatory perspective on translating proteomic biomarkers to clinical diagnostics. J Proteomics 74(12):2682–2690. doi:10.1016/j.jprot.2011.07.028

    Article  CAS  PubMed  Google Scholar 

  62. Yu PP, Hoffman MA, Hayes DF (2014) Biomarkers and oncology: the path forward to a learning health system. Arch Pathol Lab Med. doi:10.5858/arpa.2014-0080-ED

    Google Scholar 

  63. Bossuyt PM, Reitsma JB, Linnet K, Moons KG (2012) Beyond diagnostic accuracy: the clinical utility of diagnostic tests. Clin Chem 58(12):1636–1643. doi:10.1373/clinchem.2012.182576

    Article  CAS  PubMed  Google Scholar 

  64. Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101(21):1446–1452. doi:10.1093/jnci/djp335

    Article  PubMed Central  PubMed  Google Scholar 

  65. Freidlin B, McShane LM, Polley MY, Korn EL (2012) Randomized phase II trial designs with biomarkers. J Clin Oncol 30(26):3304–3309. doi:10.1200/JCO.2012.43.3946

    Article  PubMed Central  PubMed  Google Scholar 

  66. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100(20):1432–1438. doi:10.1093/jnci/djn326

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  67. IOM (2012) Evolution of translational omics: lessons learned and the path forward. Available on line: http://www.nap.edu/openbook.php?record_id=13297. Accessed 31 Dec 2014.

  68. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR (2013) Breaking a vicious cycle. Sci Transl Med 5(196):196cm196. doi:10.1126/scitranslmed.3005950

    Article  Google Scholar 

  69. Diamandis EP (2012) The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem? BMC Med 10:87. doi:10.1186/1741-7015-10-87

    Article  PubMed Central  PubMed  Google Scholar 

  70. Kern SE (2012) Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 72(23):6097–6101. doi:10.1158/0008-5472.CAN-12-3232

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  71. Ioannidis JP (2013) Biomarker failures. Clin Chem 59(1):202–204. doi:10.1373/clinchem.2012.185801

    Article  CAS  PubMed  Google Scholar 

  72. Baggerly KA, Coombes KR (2011) What information should be required to support clinical “omics” publications? Clin Chem 57(5):688–690. doi:10.1373/clinchem.2010.158618

    Article  CAS  PubMed  Google Scholar 

  73. Samuel Reich E (2011) Cancer trial errors revealed. Nature 469(7329):139–140. doi:10.1038/469139a

    Article  PubMed  CAS  Google Scholar 

  74. Diamandis EP (2003) Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 49(8):1272–1275

    Article  CAS  PubMed  Google Scholar 

  75. Diamandis EP (2004) Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96(5):353–356

    Article  PubMed  Google Scholar 

  76. Diamandis EP (2007) POINT: EPCA-2: a promising new serum biomarker for prostatic carcinoma? Clin Biochem 40(18):1437–1439. doi:10.1016/j.clinbiochem.2007.09.003

    Article  CAS  PubMed  Google Scholar 

  77. Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature 501(7467):328–337. doi:10.1038/nature12624

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  78. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C (2012) Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4(127):127ps110. doi:10.1126/scitranslmed.3003854

    Article  CAS  Google Scholar 

  79. Ginsburg GS, McCarthy JJ (2001) Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 19(12):491–496

    Article  CAS  PubMed  Google Scholar 

  80. Kalia M (2013) Personalized oncology: recent advances and future challenges. Metabolism 62(Suppl 1):S11–S14. doi:10.1016/j.metabol.2012.08.016

    Article  CAS  PubMed  Google Scholar 

  81. Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, Passiglia F, Carreca AP, Taverna S, Vento R, Peeters M, Russo A, Pauwels P (2014) Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Biophys Acta 1846(2):539–546. doi:10.1016/j.bbcan.2014.10.001

    CAS  PubMed  Google Scholar 

  82. Ross JS (2011) Cancer biomarkers, companion diagnostics and personalized oncology. Biomark Med 5(3):277–279. doi:10.2217/bmm.11.29

    Article  PubMed  Google Scholar 

  83. Schilsky RL, Doroshow JH, Leblanc M, Conley BA (2012) Development and use of integral assays in clinical trials. Clin Cancer Res 18(6):1540–1546. doi:10.1158/1078-0432.CCR-11-2202

    Article  PubMed Central  PubMed  Google Scholar 

  84. Diamandis EP (2014) Towards identification of true cancer biomarkers. BMC Med 12(1):156. doi:10.1186/s12916-014-0156-8

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  85. Alix-Panabieres C, Pantel K (2013) Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59(1):110–118. doi:10.1373/clinchem.2012.194258

    Article  CAS  PubMed  Google Scholar 

  86. Pantel K, Alix-Panabieres C (2013) Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res 73(21):6384–6388. doi:10.1158/0008-5472.CAN-13-2030

    Article  CAS  PubMed  Google Scholar 

  87. Ilie M, Hofman V, Long E, Bordone O, Selva E, Washetine K, Marquette CH, Hofman P (2014) Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med 2(11):107. doi:10.3978/j.issn.2305-5839.2014.08.11

    PubMed Central  PubMed  Google Scholar 

  88. Alix-Panabieres C, Pantel K (2014) Challenges in circulating tumour cell research. Nat Rev Cancer 14(9):623–631. doi:10.1038/nrc3820

    Article  CAS  PubMed  Google Scholar 

  89. Heitzer E, Ulz P, Geigl JB (2014) Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. doi:10.1373/clinchem.2014.222679

    PubMed  Google Scholar 

  90. Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32(6):579–586. doi:10.1200/JCO.2012.45.2011

    Article  PubMed  Google Scholar 

  91. Toss A, Mu Z, Fernandez S, Cristofanilli M (2014) CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med 2(11):108. doi:10.3978/j.issn.2305-5839.2014.09.06

    PubMed Central  PubMed  Google Scholar 

  92. Ashworth TR (1869) A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aust Med J 14:146–149

    Google Scholar 

  93. Miyamoto DT, Sequist LV, Lee RJ (2014) Circulating tumour cells-monitoring treatment response in prostate cancer. Nat Rev Clin Oncol 11(7):401–412. doi:10.1038/nrclinonc.2014.82

    Article  CAS  PubMed  Google Scholar 

  94. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Hofler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR (2013) Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 73(10):2965–2975. doi:10.1158/0008-5472.CAN-12-4140

    Article  CAS  PubMed  Google Scholar 

  95. Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253(2):180–204. doi:10.1016/j.canlet.2006.12.014

    Article  CAS  PubMed  Google Scholar 

  96. Joosse SA, Gorges TM, Pantel K (2014) Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. doi:10.15252/emmm.201303698

  97. Cristofanilli M (2006) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol 33(3 Suppl 9):S9–S14. doi:10.1053/j.seminoncol.2006.03.016

    Article  PubMed  Google Scholar 

  98. Truini A, Alama A, Dal Bello MG, Coco S, Vanni I, Rijavec E, Genova C, Barletta G, Biello F, Grossi F (2014) Clinical applications of circulating tumor cells in lung cancer patients by cell search system. Front Oncol 4:242. doi:10.3389/fonc.2014.00242

    Article  PubMed Central  PubMed  Google Scholar 

  99. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C (2014) Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 11(3):129–144. doi:10.1038/nrclinonc.2013.253

    Article  CAS  PubMed  Google Scholar 

  100. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14(9):985–990. doi:10.1038/nm.1789

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  101. Yong E (2014) Cancer biomarkers: written in blood. Nature 511(7511):524–526. doi:10.1038/511524a

    Article  CAS  PubMed  Google Scholar 

  102. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih IM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Trans Med 6(224):224ra224. doi:10.1126/scitranslmed.3007094

    Article  CAS  Google Scholar 

  103. Heitzer E, Auer M, Ulz P, Geigl JB, Speicher MR (2013) Circulating tumor cells and DNA as liquid biopsies. Genome Med 5(8):73. doi:10.1186/gm477

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  104. Ignatiadis M, Dawson SJ (2014) Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann Oncol 25(12):2304–2313. doi:10.1093/annonc/mdu480

    Article  CAS  PubMed  Google Scholar 

  105. Cheng G (2014) Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. doi:10.1016/j.addr.2014.09.001

    Google Scholar 

  106. Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20(8):460–469. doi:10.1016/j.molmed.2014.06.005

    Article  CAS  PubMed  Google Scholar 

  107. Shen J, Stass SA, Jiang F (2013) MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 329(2):125–136. doi:10.1016/j.canlet.2012.11.001

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  108. Witwer KW (2014) Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem. doi:10.1373/clinchem.2014.221341

    PubMed  Google Scholar 

  109. Schwarzenbach H, Nishida N, Calin GA, Pantel K (2014) Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11(3):145–156. doi:10.1038/nrclinonc.2014.5

    Article  CAS  PubMed  Google Scholar 

  110. Wang J, Zhang KY, Liu SM, Sen S (2014) Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules 19(2):1912–1938. doi:10.3390/molecules19021912

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Biochimica e Biochimica Clinica, Università Cattolica del S. Cuore, Largo F. Vito 1, 00168, Roma, Italy

    Alvaro Mordente, Elisabetta Meucci, Giuseppe Ettore Martorana & Andrea Silvestrini

Authors
  1. Alvaro Mordente
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabetta Meucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Ettore Martorana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Silvestrini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alvaro Mordente .

Editor information

Editors and Affiliations

  1. Institute of Biochemistry and Clinical B, Catholic University School of Medicine, Rome, Italy

    Roberto Scatena

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Mordente, A., Meucci, E., Martorana, G.E., Silvestrini, A. (2015). Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives. In: Scatena, R. (eds) Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology, vol 867. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7215-0_2

Download citation

Publish with us

Policies and ethics

Search

Navigation